mometasone | Desrinitis nasal spray 50mkg / dose 140 doses 18 g 1pc.

Latin name

DEZRINIT

Release form

Spray nasal

Packaging

1 bottle 140 doses.

Pharmacological action

Mometasone is a synthetic glucocorticosteroid (GCS) for topical use. It has anti-inflammatory and anti-allergic effects. The local anti-inflammatory effect of the drug is manifested when it is used in doses at which systemic effects do not occur.

Inhibits the release of inflammatory mediators. It increases the production of lipomodulin, which is an inhibitor of phospholipase A, which leads to a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of metabolic products of arachidonic acid - cyclic endoperoxides, prostaglandins.

Prevents marginal accumulation of neutrophils, which reduces inflammatory exudate and lymphokine production, inhibits macrophage migration, and reduces the rate of infiltration and granulation.

Reduces inflammation by reducing the formation of chemotaxis substance (affecting late allergy reactions), inhibits the development of an immediate allergic reaction (by inhibiting the formation of arachidonic acid metabolites and reducing the release of inflammatory mediators from mast cells).

In studies with provocative tests with the application of antigens to the mucous membrane of the nasal cavity, a high anti-inflammatory activity of the drug was demonstrated, both in the early and late stages of an allergic reaction.

When compared with placebo, a decrease in histamine levels and eosinophil activity, as well as a decrease (compared with the initial) in the number of eosinophils, neutrophils and proteins of epithelial cells.

Indications

Locally: attenuation and elimination of inflammatory phenomena and pruritus with dermatoses (including those with damage to the scalp), amenable to glucocorticoid therapy in adults and children over 2 years of age (including psoriasis, atopic dermatitis, seborrheic dermatitis )

Intranasal: allergic rhinitis (seasonal and year-round) in adults and children over the age of 2 years, exacerbation of sinusitis (complex therapy with antibiotics) in adults and children over 12 years of age, prevention of seasonal allergic rhinitis of moderate and severe course in adults and children over 12 years of age (recommended 2-4 weeks before the expected start of the dusting season).

Inhalation: bronchial asthma of any severity (including in patients who previously used both inhaled and systemic GCs, as well as with insufficient effectiveness of previously used therapy without using GC) COPD - from moderate to very severe.

Contraindications

Hypersensitivity for intranasal use: presence of untreated local infection involving the nasal mucosa, recent surgery or trauma to the nose (before wound healing) tuberculosis infection (active or latent), respiratory tract, untreated, fungal, Herpes simplex infection with eye damage (as an exception, the appointment of mometasone in these cases is possible as directed by a doctor with a large vanced).

Pregnancy and lactation

Possibly if the expected effect of therapy exceeds the potential risk to the fetus and child.

Composition

Active ingredient:

mometasone furoate monohydrate (in terms of mometasone furoate) 0.052 mg (0.050 mg)

Excipients:

avicel RC-591 (microcrystalline cellulose, carmellose sodium) - 2 mg,

glycerol - 2.1 mg,

benzalkonium chloride solution 500 g / l - 40 μg,

polysorbate 80 - 10 μg,

citric acid monohydrate - 200 μg,

sodium citrate dihydrate - 280 μg, srdlk d / i - qs up to 100 mg.

Dosage and administration

The dosage regimen is set individually, depending on the indications, age of the patient, route of administration, and dosage form used.

Side effects

Locally (ointment, cream, lotion): burning, itching, tingling and pricking, paresthesia, folliculitis, acne eruptions, skin atrophy, hypertrichosis, hypopigmentation, perioral dermatitis, allergic contact skin dermatitis, allergic contact dermatitis, striae, prickly heat.

Intranasal: burning, itching, irritation, dryness and atrophy of the nasal mucosa, nosebleeds, pharyngitis, candidiasis, bronchospasm, secondary infection.

Storage conditions

At 2–25 РC. (do not freeze)

Term hodnosty

3 years

Conditions of release from drugstores

Prescription of

Dosage form

spray nasal

Purpose

Antiallergic

Possible product names

Desrinitis nasal spray 50mkg / dose 140 doses 18 g 1 pc.

Teva Pharmaceutical Enterprise Co., Ltd., Israel